Clinical trial · Interventional
BAI-BACE for Advanced Lung Squamous Cell Carcinoma
Bronchial Arterial Infusion Plus Bronchial Arterial Chemoembolization (BAI-BACE) for Advanced Lung Squamous Cell Carcinoma: a Multicenter Single-arm Phase II Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Bronchial arterial infusion plus bronchial arterial chemoembolization (BAI-BACE) has been reported as non-first-line therapy to treat lung cancer in many hospitals in China. BAI, which uses chemotherapeutic drugs directly injected into the tumor and achieved a high concentration in a short time to kill the tumor. Then BACE could seal off the tumor vessels. In this study, we aim to describe the efficacy and safety of BAI-BACE as non-first-line for advanced lung squamous cell carcinoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Squamous Cell Carcinoma | Squamous Cell Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| BAI-BACE | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- BAI-BACE
- description
- Bronchial arterial infusion, bronchial arterial chemoembolization (BACE-BAI)
- interventionNames
- Procedure: BAI-BACE
Primary outcomes (1)
- measure
- Progression-Free-Survival (PFS)
- timeFrame
- 12 months
- description
- Progression was defined as progressive disease by independent radiologic review
Secondary outcomes (3)
- measure
- Overall survival (OS)
- timeFrame
- 24 months
- description
- OS is the length of time from the date of inclusion until death from any cause.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. Squamous cell carcinoma diagnosed by pathology, and central location by imaging; 2. Age 18-80; 3. Patients failed to the standard first-line or second-line treatment; 4. Tumors limited in the chest; 5. Tumors were fed by bronchial artery through CTA reconstruction; 6. Patents received PD-1 inhibitor or not were also included; 7. Eastern Cooperative Oncology Group performance status (ECOG PS) of 0-2; 8. Images within 2 weeks before inclusion; 9. Life expectancy more than 3 months; 10. Agreed to participated in this clinical trial; 11. Hemameba ≥3.0 x109/L, neutrophil ≥1.5x109/L, hemoglobin≥10.0 g/L, platelet≥100x 109/L, ALT; AST; bilirubin ≤1.5-fold normal, GFR≥60ml/min. Exclusion Criteria: 1. Contraindication of BAI or BACE; 2. Under 18 years or over 75 years; 3. extra-chest metastases; 4. Receiving other antitumor treatment; 5. Severe infection or pregnancy; 6. Severe Pulmonary fibrosis and pulmonary artery; 7. liver, kidney or poor physical conditions; 8. Severe pleural effusion or pericardial effusion; 9. Life expectancy less than 3 months.
References
Publications (0)
Data not yet available